CompoAtlas

Vega Sport Pre-Workout Energizer

Natural health product licensed in Canada

If this product were sold in France

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Alpha-D-Glucopyranosyl-bêta-D-fructofuranoside

Source : Acer saccharum - sap

9,500 milligrammeNot calculated
Alpha-D-Glucopyranosyl-bêta-D-fructofuranoside

Source : Borassus flabellifer - sap

9,500 milligrammeNot calculated
Chlorure de magnésium

Source : Chlorure de magnésium

Potency : 41 % Magnesium

13 milligrammeNot calculated
Beta vulgaris

Source : Racine

Potency : 2 % Nitrate

1,000 milligrammeNot calculated
Camellia sinensis

Source : Feuille

Extraction ratio : 11:1

Dry plant equivalent : 8,250 milligramme

Potency : 10 % Caffeine

750 milligrammeNot calculated
Rhodiola rosea

Source : Racine

Potency : 1 % Salidroside

Not specifiedNot calculated
Camellia sinensis

Source : Feuille

Extraction ratio : 10.5:1

Dry plant equivalent : 4,725 milligramme

Potency : 5.5 % Caffeine

450 milligrammeNot calculated
Chlorure de calcium anhydre(CaCl2)

Source : Chlorure de calcium

Potency : 53 % Calcium

20 milligrammeNot calculated
Theobroma cacao

Source : Graine(s)

Extraction ratio : 5.2:1

Dry plant equivalent : 1,040 milligramme

Potency : 0.5 % Caffeine

200 milligrammeNot calculated
Harpagophytum procumbens

Source : Racine(s) secondaire(s) tubérisée(s)

Extraction ratio : 6:1

Dry plant equivalent : 660 milligramme

110 milligrammeNot calculated
Panax ginseng

Source : Racine

Extraction ratio : 5:1

Dry plant equivalent : 575 milligramme

Potency : 7 % Total ginsenosides

115 milligrammeNot calculated
Rhodiola rosea

Source : Racine

Extraction ratio : 5:1

Dry plant equivalent : 750 milligramme

Potency : 3 % Rosavins

150 milligrammeNot calculated
Curcuma longa

Source : Rhizome

Extraction ratio : 37.5:1

Dry plant equivalent : 2,062.5 milligramme

Potency : 95 % Curcuminoids

55 milligrammeNot calculated
Piper nigrum

Source : Fruit

Extraction ratio : 25:1

Dry plant equivalent : 12.5 milligramme

Potency : 95 % Piperine

0.5 milligrammeNot calculated
Chlorure de sodium

Source : Chlorure de sodium

Potency : 39 % Sodium

260 milligrammeNot calculated
Chlorure de potassium

Source : Chlorure de potassium

Potency : 52 % Potassium

60 milligrammeNot calculated

Non-medicinal ingredients

Acide citrique, Saveur, Feuille de Stevia rebaudiana

PopulationAgeQuantity per servingFrequency
AdultesNot specified1 Portion(s)1 Tous les jours

Uses authorised in Canada

Workout supplement. Athletic support. Source of carbohydrates to support energy production. Source of calories which contributes to weight gain. Helps to [maintain performance/promote endurance] in extended (greater than 60 min), high intensity exercise. Helps (temporarily) to relieve fatigue, to promote endurance, and to enhance motor performance. Devils claw is used in Herbal Medicine to help relieve joint pain associated with osteoarthritis. Panax ginseng is used in Herbal Medicine to help enhance physical capacity/performance (in cases of physical stress). Source of/Provides antioxidants that help fight/protect cell against/reduce the oxidative effect of/the oxidative damage caused by/cell damage caused by free radicals. Used in Herbal Medicine (as an adaptogen) to help temporary relieve symptoms of stress (such as mental fatigue and sensation of weakness) and to help support cognitive function (such as mental focus and mental stamina). Turmeric is traditionally used in Herbal Medicine as an anti-inflammatory to help relieve joint pain. Source of electrolyte.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

Product record

Licence holder
Sequel Naturals ULC/dba Vega
NPN or DIN-HM
80069448
Status
Inactive licence
Licence date
16 May 2016
Revision date
Not provided
Form
Poudre
Route of administration
Orale
Application type
Non traditionnelle

Source

Official Health Canada record, licence 80069448

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Harpagophytum procumbens
    Read the warning, when it applies and the studies cited

    DEVIL'S CLAW - HARPAGOPHYTUM

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Health Canada monograph dated 27 March 2026

  • Panax ginseng
    Read the warning, when it applies and the studies cited

    PANAX GINSENG

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Vuksan et al. 2008; Seely et al. 2008; Sievenpiper et al. 2006; ESCOP 2003; Tetsutani et al. 2000; Sotaniemi et al. 1995; Chin 1991).

    Sources cited by Health Canada (8)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Chin RKH. Ginseng and common pregnancy disorders. Asia-Oceania Journal of Obstetrics and Gynaecology 1991;17(4):379-380. PubMed
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Seely D, Dugoua JJ, Perri D, Mills E, Koren G. Safety and efficacy of Panax ginseng during pregnancy and lactation. The Canadian Journal of Clinical Pharmacology 2008;15(1):e87-e94.
    • Sievenpiper JL, Sung MK, Buono MD, Seung-Lee K, Nam KY, Arnason JT, Leiter LA, Vuksan V. Korean red ginseng rootlets decrease acute postprandial glycemia: results from sequential preparation- and dose-finding studies. Journal of the American College of Nutrition 2006;25(2):100-107. PubMed Randomised trial
    • Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care 1995;18(10):1373-1375. PubMed Clinical trial
    • Tetsutani T, Yamamura M, Yamaguchi T, Onoyama O, Kono M. Can red ginseng control blood glucose in diabetic patients. The Ginseng Review 2000;28:44-47.
    • Vuksan V, Sung MK, Sievenpiper JL, Stavro PM, Jenkins AL, Buono MD, Lee KS, Leiter LA, Nam KY, Arnason JT, Choi M, Naeem A. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutrition, Metabolism & Cardiovascular Diseases 2008;18(1):46-56. PubMed Randomised trial

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking antidepressant medication, blood thinners or digoxin (Brinker 2010; Lee et al. 2008a; Dasgupta and Reyes 2005; Janetzki and Morreale 1997; Gonzalez-Seijo et al. 1995; Shader and Greenblatt 1988; Jones and Runikis 1987; Shader and Greenblatt 1985).

    Sources cited by Health Canada (8)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Dasgupta A, Reyes MA. Effect of Brazillian, Indian, Siberian, Asian, and North American ginseng on serum digoxin measurement by immunoassays and binding of digoxin-like immunoreactive components of ginseng with Fab Fragment of antidigoxin antibody (Digiband). American Journal of Clinical Pathology 2005;124(2):229-236. PubMed
    • Gonzalez-Seijo JC, Ramos YM, Lastra I. Manic episode and ginseng: report of a possible case. Journal of Clinical Psychopharmacology 1995;15(6):447-448. PubMed Case report
    • Janetzki K, Morreale AP. Probable interaction between warfarin and ginseng. American Journal of Health-System Pharmacy 1997;54(6):692-693.
    • Jones BD, Runikis AM. Interaction of ginseng with phenelzine. Journal of Clinical Pharmacology 1987;7(3):201-202. PubMed Case report
    • Lee SH, Ahn YM, Ahn SY, Doo HK, Lee BC. Interaction between warfarin and Panax ginseng in ischemic stroke patients. The Journal of Alternative and Complementary Medicine 2008a;14(6):715-721. PubMed Randomised trial
    • Shader RI, Greenblatt DJ. Bees, ginseng and MAOIs revisited. Journal of Clinical Psychopharmacology 1988;8(4):235. PubMed Case report
    • Shader RI, Greenblatt DJ. Phenelzine and the dream machine – ramblings and reflections. Journal of Clinical Psychopharmacology 1985;5(2):65. PubMed Case report

    Contraindications

    Condition of application: Traditional Chinese Medicine.

    Do not use in cases of yin deficiency with heat signs, heat excess, or in the absence of significant qi deficiency (Bensky et al. 2004).

    Sources cited by Health Canada (1)
    • Bensky D, Clavey, Stöger E, Gamble A. Chinese Herbal Medicine: Materia Medica. 3rd edition. Seattle (WA): Eastland Press, Incorporated; 2004.

    Known adverse reactions

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience insomnia, anxiety or headaches (Lee et al. 2008b; Vuksan et al 2008; de Andrade et al.2007; Sievenpiper et al. 2006; Coon and Ernst 2002; Ellis and Reddy 2002; Scaglione et al. 2001; Siegel 1979).

    Sources cited by Health Canada (8)
    • Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Safety 2002;25(5):323-344. PubMed Systematic review
    • de Andrade E, de Masquita AA, de Almeida Claro J, de Andrade PM, Ortiz V, Paranhos M, Srougi M. Study of the efficacy of Korean Red Ginseng in the treatment of erectile dysfunction. Asian Journal of Andrology 2007;9(2):241-244.
    • Ellis JM, Reddy P. Effects of Panax ginseng on quality of life. The Annals of Pharmacotherapy 2002;36(3):375-379. PubMed Randomised trial
    • Lee ST, Chu K, Sim JY, Heo JH, Kim M. Panax ginseng enhances cognitive performance in Alzheimer disease. Alzheimer Disease and Associated Disorders 2008b;22(3):222-226. PubMed Randomised trial
    • Scaglione F, Weiser K, Alessandria M. Effects of the standardised ginseng extract G115 in patients with chronic bronchitis. Clinical Drug Investigation 2001;21(1):41-45.
    • Siegel RK. Ginseng abuse syndrome. Problems with the panacea. The Journal of the American Medical Association 1979;241(15):1614-1615. PubMed
    • Sievenpiper JL, Sung MK, Buono MD, Seung-Lee K, Nam KY, Arnason JT, Leiter LA, Vuksan V. Korean red ginseng rootlets decrease acute postprandial glycemia: results from sequential preparation- and dose-finding studies. Journal of the American College of Nutrition 2006;25(2):100-107. PubMed Randomised trial
    • Vuksan V, Sung MK, Sievenpiper JL, Stavro PM, Jenkins AL, Buono MD, Lee KS, Leiter LA, Nam KY, Arnason JT, Choi M, Naeem A. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutrition, Metabolism & Cardiovascular Diseases 2008;18(1):46-56. PubMed Randomised trial

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 27 June 2025

  • Curcuma longa
    Read the warning, when it applies and the studies cited

    TURMERIC - CURCUMA LONGA - Oral

    Route of administration: Oral (ESCOP 2003; Blumenthal et al. 2000)

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (ESCOP 2003; Brinker 2001; McGuffin et al. 1997).

    Sources cited by Health Canada (2)
    • ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder (HC 2025; EMA 2018; Brinker 2010; ESCOP 2003; McGuffin et al. 1997).

    Sources cited by Health Canada (6)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2018. European Medicines Agency. European Union herbal monograph on Curcuma longa L., rhizome. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 25 September 2018. [Accessed 2023 October 14] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-curcuma-longa-l-rhizoma-revision-1_en.pdf
    • ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
    • SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications (HC 2025).

    Sources cited by Health Canada (2)
    • HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
    • SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience any new symptoms including yellowing of the eyes or skin, dark urine, nausea, vomiting, stomach pain (HC 2025).

    Sources cited by Health Canada (2)
    • HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
    • SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867

    Condition of application: All uses except for Source of antioxidants and Hepatoprotectant.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 26 September 2025

    Turmeric -CURCUMA LONGA - Topical

    Cautions and warnings

    For external use only.

    When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.

    Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.

    Contraindications

    Do not use on deep or puncture wounds, animal bites or serious burns.

    Health Canada monograph dated 28 February 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Vega Sport Pre-Workout Energizer”, https://compoatlas.com/en/supplements/canada/80069448-vega-sport-pre-workout-energizer, updated 16 May 2016.

Enter to analyse, Shift+Enter for a new line